Friday, 19 October
12:00-14:00 Registration Open
14:00-15:00 Congress Opening Ceremony. European Hematology Association (EHA)- Estonian Society of Hematology Joint Session
15:00-15:45 Chair: Kadri Saks
Sanofi satellite session: Application of Next-Generation Sequencing (NGS)-based genetic screenings to hematologic disease: the case of lysosomal storage disorders and their differential diagnoses – Francisco J.del Castillo
16:00-17:30 Session I – ALL Chair: Kadri Saks, Mari Punab
16:00-16:30 Update on Minimal Residual Disease in ALL – Anna Porwit
16:30-17:00 New trends in ALL therapy: what is changing with ALLTogether – Mervi Taskinen
17:00-17:15 Acute de novo lymphoblastic leukemia in adults in Estonia during 2007-2017: incidence, treatment modalities and survival – Mari Punab
17:15-17:30 Cytokine receptor and kinase signaling pathway activating alterations in pediatric and adult B-other ALL – Rimvydas Norvilas
17:30-17:45 Acute lymphoblastic leukemia (ALL) in Estonian children from 2008 to 2018: 10 year treatment results with NOPHO ALL-2008 protocol – Maarja Karu
17:45-18:30 Chair: Mariken Ross
Pfizer Satellite session: Antibody directed approached in acute lymphoid leukemias – David Marks
Saturday, 20 October
08:00-09:30 II session: CLL/ hematological malignancies
Chair: Iige Viigimaa, Sandra Lejniece
08:00-8:30 CLL: an update with focus on conventional therapy Eva Kimby
08:30-9:00 Current diagnostic and therapeutic recommendations for CLL – Tadeusz Robak
09:00-9:15 First results of Venetoclax in combination with low dose Cytarabine or Actinomycin D in relapsed/refractory acute leukemia patients – Andrius Zucenka
09:15-9:30 Time from symptom onset to diagnosis and treatment among hematological malignancies: influencing factors and associated negative outcomes – Austeja Dapkeviciute
09:45-11:15 Session III – Lymphoma I
Chair: Ugne Ringeleviciute, Hele Everaus
09:45-10:15 CAR019 therapy in relapsed Diffuse large B-cell lymphomas: Experience from an international multicenter study – Harald Holte
10:15-10:45 Children’s non-Hodgkin lymphoma – actual status of treatment studies in the European Intergroup – Karin Mellgren
10:45-11:00 Epidemiology and treatment of HIV-associated lymphomas in Estonia – Iige Viigimaa
11:00-11:15 The spectrum of lymphoproliferative diseases in Lithuania 2010-2016: how are we different from the west? – Ugne Ringeleviciute
11:30-13:05 IV sessioon: Plasma Cell disorders, including Waldenström’s Macroglobulinemia
Chair:Valdas Peceliunas, Evangelos Terpos
11:30-12:00 Genomic and Treatment Advances in Waldenstrom’s Macroglobulinemia – Steven Treon
12:00-12:30 Optimal sequencing of treatment for ASCT non eligible patients – Evangelos Terpos
12:30-12:45 Genomic Instability in Multiple Myeloma – Edward Laane
12:45-13:05 Systems Medicine Approach for Individualized Management of Lymphoproliferative Malignancies-a Novel Way for the Progress? – Hele Everaus
14:00-15:00 Chair:Iige Viigimaa
Janssen satellit session: Clinical Approach to Patients with High Molecular Risk Chronic Lymphocytic Leukemia – Davide Rossi
15:05-17:00 V sessioon: Lymfoma II
Chair:Edward Laane, Ilze Trociukas
15:05-15:35 1st line and PET-response adapted treatment in Hodgkin’s lymphoma- Martin Hutchings 15:35-16:05 Treatment of relapsed/refractory Hodgkin’s lymphoma – Martin Hutchings
16:05-16:35 Assessing patient-reported outcomes in lymphoma patients: why, when and how. – Tatyana Ionova
16:35-16:50 B follicular lymphoma in Lithuania 2008-2017: incidence, evolution, survival – Ugne Ringeleviciute
16:50-17:05 Brentuximab vedotin and nivolumab in relapsed/refractory Hodgkin lymphoma: Estonian experience – Julia Abubikirova
17:05-17:20 Conclusions from the day